Introduction
Leading global biosimilars company secured full global rights for biosimilar Adalimumab Hulio from FKB, gaining responsibility for manufacturing, commercialization, and development across worldwide markets following expanded in licensing agreement.
Also Read: GE Vernova stock jumps 11% after HVDC contract from AESL Projects
Share price movement of Biocon
On December 23, 2025, Biocon Ltd opened at ₹400.10, up 0.26% from its previous close of ₹399.05. The stock reached a high of ₹403.70 (1.13%) and a low of ₹399.45 (0.10%). By 11:10 AM, it traded at ₹400.90, a 0.46% increase, with a market capitalization of ₹53,598.87 crore.
Biocon Biologics Secures Global Adalimumab Rights
Biocon Biologics Limited, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced securing full global rights for biosimilar Adalimumab Hulio from Fujifilm Kyowa Kirin Biologics under an expanded in licensing agreement dated December 23 2025 in Bengaluru India.
The new agreement replaces the earlier collaboration where Biocon Biologics held only commercialization rights and now grants manufacturing commercialization and additional development responsibilities for the biosimilar across global markets worldwide.
Under the terms FKB will support development and offset certain costs while Biocon Biologics will pay license fees royalties and begin commercial production after technology transfer and regulatory approvals completion.
Stock performance of Biocon for Period of 1 week, 6 months, and 1 year
Biocon Ltd delivered a 3.74% return over the past week. It gained 13.9% over the past six months and rose 21.2% over the past year.
Shareholding pattern of Biocon
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 54.50% | 54.50% | 60.60% |
| FII | 6.60% | 6% | 6% |
| DII | 22% | 23% | 15.70% |
| Public | 16.70% | 16.50% | 18% |
| Others | 0.20% | 0.20% | 0.20% |
About Biocon
Biocon Limited (NSE: BIOCON), a global biosimilars company, develops and commercializes high-quality affordable biologics, serving 6.3 million patients across 120+ countries with 10 launched products and 20+ pipeline assets.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Biocon share price going up today?
A: Biocon share price is rising after securing full global rights for biosimilar Adalimumab Hulio from FKB under an expanded in-licensing agreement.
Q: What does Biocon Ltd specialize in?
A: Biocon Ltd specializes in developing and commercializing global biosimilars, providing affordable biologics across diabetology, oncology, immunology, ophthalmology, and other therapeutic areas.
Q: What is the 52-week high and low of Biocon stock?
A: Biocon stock has a 52-week high of ₹424.95 and a 52-week low of ₹290.80 as per recent data.
